Experience

Alani Nu’s $1.8 Billion Sale to Celsius

February 20, 2025

Cooley advised Katy Hearn and Haydn Schneider, co-founders of Alani Nu, in connection with Celsius Holdings’ (Nasdaq: CELH) definitive agreement to acquire the company for $1.8 billion in cash and stock.

Read more

Related contacts

Bill Roegge
Partner, New York
Stephanie Leigh
Paralegal Specialist, San Diego
Stephanie Gentile
Partner, New York
Jeremy Morrison
Partner, Washington, DC
Vicky Kandabarow
Associate, Washington, DC
Kyle Hess
Associate, New York
Wesley Dietrich
Associate, Washington, DC
Sharon Connaughton
Special Counsel, Washington, DC
Todd Gluth
Partner, San Diego
Sarah Lightdale
Partner, New York
Eileen Marshall
Partner, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Julia R. Brinton
Special Counsel, Washington, DC
William Corcoran
Of Counsel, Boston

Related Practices & Industries

Poseida Therapeutics – $80.5 Million Follow-on Offering

September 7, 2022

Cooley advised the issuer for Poseida Therapeutics’ $80.5 million follow-on offering of 23,000,000 shares of common stock at a public offering price of $3.50 per share. Poseida is a clinical-stage biopharmaceutical company dedicated to utilizing its proprietary genetic engineering platform technologies to create next-generation cell and gene therapeutics. Partners Tom Coll and Charlie Kim led the Cooley team.

Related contacts

Tom Coll
Partner, San Diego
Charlie Kim
Partner, San Diego
Asa Henin
Partner, San Diego
Edmond Lay
Partner, San Diego
Heidi E. Wang
Associate, San Diego
Stephanie Leigh
Paralegal Specialist, San Diego
Kelly Nelle
Paralegal Specialist, San Diego

Related Practices & Industries

Kronos Bio – $288 million IPO

October 8, 2020

Cooley advised Kronos Bio on its $287.5 million initial public offering of 15,131,579 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. Kronos Bio, whose securities now trade on the Nasdaq Global Select Market under the symbol KRON, is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics. Partners Charles Bair, Charlie Kim and Chad Mills led the Cooley team.

Related contacts

Charles Bair
Partner, San Diego
Chadwick Mills
Partner, San Francisco
Asa Henin
Partner, San Diego
Brett Dovman
Associate, San Diego
Stephanie Leigh
Paralegal Specialist, San Diego
Kate Walther
Paralegal Specialist, San Diego

Related Practices & Industries

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.